Table 2.
Patient characteristics and pulmonary function data.
| Participants (n = 26) | |
|---|---|
| Age, years | 26.5 ± 7.9 (19–50) |
| Gender | |
| Female, n (%) | 8 (31) |
| Male, n (%) | 18 (69) |
| Genotype | |
| F508del homozygous, n (%) | 17 (65) |
| F508del heterozygous, n (%) | 6 (23) |
| Other, n (%) | 3 (12) |
| BMI, kg/m2 | 19.6 ± 2.7 (16-28) |
| FEV1, L | 2.1 ± 1.0 (0.7–4.4) |
| FEV1, % predicted | 53.7 ± 21.0 (17–98) |
| FVC, L | 3.2 ± 1.2 (1.6–5.7) |
| FVC, % predicted | 67.7 ± 20.0 (28–102) |
| Pancreatic insufficiency, n (%) | 21 (81) |
| P. aeruginosa positive, n (%) | 15 (58) |
| Cystic fibrosis-related diabetes, n (%) | 7 (27) |
| O2 supplementation, n (%) | 4 (15) |
Results are presented as mean ± standard deviation (SD) and range or number of patients n (%). BMI: body mass index; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity.